Companion Medical, Glooko ink InPen insulin pen data integration deal

Companion Medical said today that it inked a partnership deal with Glooko to integrate data from its InPen smart insulin injection pen into Glooko’s diabetes data management system and mobile application.

The integration will be performed through Apple‘s (NSDQ:AAPL) Apple Health application, San Diego-based Companion Medical said, and will allow users to automatically integrate insulin data with Glooko’s platforms for clinical evaluation by healthcare professionals.

“We are thrilled to be working with Glooko to bring integrated multiple daily injection insulin data into the Glooko system. Our mission is to bring insulin data together with glucose and other contextual data in a way that is seamless, easy and automatic for both healthcare professionals and their patients. Our partnership with Glooko is an important step in that mission,” Companion Medical CEO Sean Saint said in a prepared statement.

Companion Medical touted that the deal marks the first “smart” insulin pen integrated into Glooko’s network, adding that more than 70% of the 7.4 million insulin users in the U.S. take their insulin via multiple daily injections, half of which use an insulin pen.

“We are excited to launch support for InPen on the Glooko platform. InPen is an innovative solution for calculating insulin doses and tracking insulin injection data. We feel users will get tremendous value out of seeing this data correlated with the food, activity, and glucose information in Glooko to help them make informed treatment decisions when they dose and see diabetes insights and trends over time that may not have been previously known,” Glooko CEO Russ Johannesson said in a press release.

“We believe this is a huge step forward in the development of integrated diabetes management because it allows data never seen before, both long and short-acting insulin, to be integrated with other diabetes data residing in the Glooko platform without the need for downloading or manually entering data,” said Companion Medical chief tech officer Mike Mensinger said in prepared remarks.

Last July, Companion Medical said that it won CE Mark approval in the European Union for its InPen smart insulin pen and associated diabetes management smartphone application.